Mid Cap Biotechnology
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
51
Dyne Therapeutics
DYN
$2.66B
| $2.66B | $14.25 | 6.8% |
|
52
Zai Lab
ZLAB
$2.6B
| $2.6B | $23.19 | 1.36% |
|
53
Beam Therapeutics
BEAM
$2.42B
| $2.42B | $23.47 | 5.1% |
|
54
ADMA Biologics
ADMA
$2.39B
| $2.39B | $10.68 | 0.47% |
|
55
MBX Biosciences
MBX
$2.39B
| $2.39B | $49.61 | 2.17% |
|
56
NewAmsterdam Pharma
NAMS
$2.37B
| $2.37B | $19.83 | 3.83% |
|
57
Precigen
PGEN
$2.28B
| $2.28B | $6.38 | 11.4% |
|
58
Harmony Biosciences
HRMY
$2.21B
| $2.21B | $37.95 | 0.84% |
|
59
Aurinia Pharmaceuticals
AUPH
$2.2B
| $2.2B | $16.51 | 1.32% |
|
60
Disc Medicine
IRON
$2.18B
| $2.18B | $56.84 | 0.34% |
|
61
Celldex Therapeutics
CLDX
$2.16B
| $2.16B | $27.53 | 4.84% |
|
62
Viridian Therapeutics
VRDN
$2.16B
| $2.16B | $19.03 | 2.71% |
|
63
Fortrea Holdings
FTRE
$2.14B
| $2.14B | $22.49 | 1.14% |
|
64
Vericel Corp
VCEL
$2.05B
| $2.05B | $40.13 | 2.17% |
|
65
SELLAS Life Sciences
SLS
$2.02B
| $2.02B | $9.98 | 12% |
|
66
Vera Therapeutics
VERA
$2.01B
| $2.01B | $27.88 | 2.42% |
|
Mid Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 66 mid cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $2B and $10B — worth a combined $302B.
The largest by market cap are ImmunityBio (IBRX) at $9.7B, Krystal Biotech (KRYS) at $9.37B and Twist Bioscience (TWST) at $8.8B.
Among institutional investors, Definium Therapeutics (DFTX) drew the most net new fund positions in Q2 2026: 148 funds opened new positions, taking total fund holders up 114 (46%) quarter-over-quarter.
- Combined market cap: $302B across 66 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: ImmunityBio (IBRX), $9.7B market cap.
- Most net new fund positions in Q2 2026: Definium Therapeutics (DFTX), +114 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.